Covidien Ltd.
15 Hampshire Street
Mansfield, MA 02048
USA
Product Categories:
Interventional Radiology
Interventional Radiology
RELATED CONTENT
Feature | Raissa Rocha
The use of contrast media in many imaging modalities continues to evolve as physicians seek to improve dose management practices and vendors churn out automated injectors that can precisely control the amount of contrast and personalize doses for patients using information pulled from an electronic medical record (EMR) or picture archiving and communication system (PACS). The features of today’s contrast media injectors include syringeless options and dose recording software, offering new possibilities for radiology departments looking to streamline and document their contrast media usage.
October 03, 2014 
News
U.S.-based Medtronic said it would purchase Ireland-based Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping Medtronic savings with a headquarters change.
September 11, 2014 
Feature | Dave Fornell
Two next-generation automated contrast injector systems were recently introduced in the United States.
May 15, 2012 
Technology
March 7, 2012 — Covidien announced the global launch of the Optivantage dual-head computed tomography (CT) contrast media delivery system with simultaneous injection.
March 07, 2012 News
February 17, 2010 — An agreement has been reached to further augment and diversify a manufacturer's supply of molybdenum 99 (Mo 99) to produce the medical isotope technetium 99m (Tc 99m).
February 17, 2010 
News
December 18, 2009 - The U.S. radiopharmacy network currently owned by Covidien is being sold to Triad Isotopes in a deal announced today.
Covidien said it decided to divest its network of 37 Mallinckrodt radiopharmacies after evaluating the radiotracer market. The company said it wants to streamline its portfolio and concentrate resources in its faster-growing, higher-margin businesses.
December 18, 2009 
News
November 10, 2009 – Covidien said yesterday it will voluntarily contraindicate the use of its Optimark gadoversetamide injection, a gadolinium-based contrast agent (GBCA), in magnetic resonance imaging (MRI) procedures involving patients with severe renal impairment.
November 10, 2009 News
July 8, 2009 - Covidien said today Health Canada approved the company’s abbreviated new drug submission (ANDS) for its kit for the preparation of technetium Tc 99m Sestamibi injection.
Covidien’s generic product is fully substitutable for Cardiolite, the company said.
July 08, 2009 Feature
June 16, 2009 - In response to the molybdenum 99 (Mo-99) supply shortage, Covidien sent out a letter to its customers informing them of the anticipated Covidien generator and unit dose (UD) Tc 99m supply to the overall U.S., Canadian and Latin American markets through August 2009.
June 16, 2009 News
March 5, 2009 - Covidien recently launched www.colondisease.com, designed to be easy-to-use, patient-oriented Web site filled with vital information on colorectal disease, including symptoms, treatments and surgical options for various types of colon disease.
March 06, 2009 